Incyte's financial health is anchored by its blockbuster JAK inhibitor, Jakafi, for rare blood cancers, and its fast-growing dermatology cream, Opzelura, approved to treat vitiligo and eczema. In the ...

The acquisition will bring navtemadlin, Kartos' late-stage treatment program in myelofibrosis, to Ipsen's pipeline.

Incyte's valuation still appears attractive if pipeline execution continues and analysts eventually raise long-term ...

Bill Meury says his company now has blood, cancer, and immune treatments to replace sales from its top-selling drug, Jakafi, ...

French pharma company Ipsen has agreed to buy cancer biotech Kartos Therapeutics of the US for $450 million upfront, gaining ...

Incyte Corporation has reached an agreement with the Centers for Medicare & Medicaid Services to resolve litigation over the application of Medicaid rebate rules to Opzelura, its ruxolitinib cream.

Biotech stock Incyte is working its way up toward a pivot at 112.29, extending a two-day winning streak.

Incyte said on Monday it will buy Vega ​Therapeutics, a wholly owned subsidiary of privately held Star Therapeutics, in a deal ‌worth up to $2 billion, expanding its pipeline for blood disorder ...

In recent weeks, Incyte reported first-quarter 2026 results showing revenue of US$1,272.68 million and net income of US$303.33 million, reaffirmed its 2026 net sales guidance of US$4.77 ...

Incyte primarily derives product revenues from the sales of its lead drug, Jakafi (ruxolitinib), in the United States, as well as from the sales of other marketed drugs. Its momentum is likely to have ...